{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:55:39Z","timestamp":1789606539385,"version":"build-2803163510"},"reference-count":23,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01DA044526-01A1"],"award-info":[{"award-number":["1R01DA044526-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["3UG1DA015831-17S2"],"award-info":[{"award-number":["3UG1DA015831-17S2"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000058","name":"Substance Abuse and Mental Health Services Administration","doi-asserted-by":"publisher","award":["1H79TI081442-01"],"award-info":[{"award-number":["1H79TI081442-01"]}],"id":[{"id":"10.13039\/100000058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009827","name":"Laura and John Arnold Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009827","id-type":"DOI","asserted-by":"publisher"}]},{"name":"OptumLabs"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Abuse"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Substance use disorder (SUD) treatment in general medical settings remains underutilized. We evaluated 5 years of a hospital-wide SUD initiative which included an inpatient addiction consult team (ACT), low-threshold Bridge Clinic, recovery coaches, and office-based addiction treatment (OBAT) nurses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Naturalistic registry study. We calculated frequencies of patient contacts, types of substance use diagnoses, and medication treatment initiation and duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 2014 to 2019, 7,036 unique patients were seen, including 4,959 by ACT, 1,197 in Bridge Clinic, 2,250 by a recovery coach, and 979 by an OBAT nurse. The median age was 47, 31% were women, 80% were white, 7% were black, 6% were Hispanic\/Latinx, and 25% were experiencing homelessness. Alcohol use disorder was seen in 62%, opioid use disorder in 54%, cocaine use disorder in 29%, benzodiazepine use disorder in 14%, and stimulant use disorder in 7%. Co-occurring medical and psychiatric illnesses were common; 35% had hepatitis C, 59% depression, 66% anxiety, and 13% schizophrenia. 1,623 patients received a prescription for buprenorphine during the study period (42% of patients with OUD), 877 for oral naltrexone, and 163 for extended-release naltrexone. The mean length of continuous treatment was 178.4\u2009days for buprenorphine, 47.7\u2009days for oral naltrexone, and 1.29 injections for extended-release naltrexone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"conclusions\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A hospital SUD initiative effectively initiated SUD pharmacotherapy with naltrexone and buprenorphine. Medication treatment episodes were longer with buprenorphine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1080\/08897077.2020.1846664","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T15:49:35Z","timestamp":1607010575000},"page":"767-774","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":28,"title":["A hospital-wide initiative to redesign substance use disorder care: Impact on pharmacotherapy initiation"],"prefix":"10.1177","volume":"42","author":[{"given":"Sarah E.","family":"Wakeman","sequence":"first","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Kane","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Powell","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Howard","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Shaw","sequence":"additional","affiliation":[{"name":"Department of Nursing and Patient Care Services, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Kehoe","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Rosen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Quinlan","sequence":"additional","affiliation":[{"name":"Center for Community Health Improvement, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Regan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,10,1]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"Substance Abuse and Mental Health Services Administration. 2019. Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068 NSDUH Series H-54). Rockville MD: Center for Behavioral Health Statistics and Quality Substance Abuse and Mental Health Services Administration. https:\/\/www.samhsa.gov\/data\/. Accessed February 3 2020."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.2161"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2018.304673"},{"key":"e_1_3_4_5_2","volume-title":"Opioid-Related Inpatient Stays and Emergency Department Visits by State, 2009\u20132014. HCUP Statistical Brief #219","author":"Weiss AJ","year":"2016","unstructured":"Weiss AJ, , Elixhauser A, , Barrett ML, , Steiner CA, , Bailey MK, , O'Malley L. Opioid-Related Inpatient Stays and Emergency Department Visits by State, 2009\u20132014. HCUP Statistical Brief #219. Rockville, MD: Agency for Healthcare Research and Quality; 2016. http:\/\/www.hcup-us.ahrq.gov\/reports\/statbriefs\/sb219-Opioid-Hospital-Stays-ED-Visits-by-State.pdf."},{"key":"e_1_3_4_6_2","unstructured":"Centers for Disease Control and Prevention. Annual Surveillance Report of Drug-Related Risks and Outcomes \u2014 United States 2017. Surveillance Special Report 1. Centers for Disease Control and Prevention U.S. Department of Health and Human Services. https:\/\/www.cdc.gov\/drugoverdose\/pdf\/pubs\/2017cdc-drug-surveillance-report.pdf. Published August 31 2017. Accessed November 20 2017."},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6817a3"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2015.06.010"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-010-1311-3"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.2556"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3474"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-017-4077-z"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-018-4807-x"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-019-05251-9"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.07.005"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622"},{"issue":"2","key":"e_1_3_4_17_2","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick RP","year":"2014","unstructured":"Mattick RP, , Breen C, , Kimber J, , Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2(2):CD002207.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.06.039"},{"key":"e_1_3_4_19_2","unstructured":"The Massachusetts Board of Substance Abuse Counselor Certification. CARC Information and Requirements. Available online at https:\/\/www.mbsacc.com\/carc. Accessed July 14 2020."},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2012.741167"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2017.0745"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.0876"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.7326\/M17-3107"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2012.12004.x"}],"container-title":["Substance Abuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2020.1846664","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1080\/08897077.2020.1846664","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2020.1846664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:32:59Z","timestamp":1780507979000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1080\/08897077.2020.1846664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1080\/08897077.2020.1846664"],"URL":"https:\/\/doi.org\/10.1080\/08897077.2020.1846664","relation":{},"ISSN":["0889-7077","1547-0164"],"issn-type":[{"value":"0889-7077","type":"print"},{"value":"1547-0164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}